CompanyDrug

Sanofi’s Amlitelimab Shows Promising Phase IIb Results in Atopic Dermatitis, Potential for 12-Week Dosing

CompanyDeals

Jiangsu QYuns Therapeutics Eyes HK IPO to Raise Up to HKD 243 Million for Autoimmune Pipeline

Company

Legend Biotech Reports Q4 and Full-Year 2023 Financials with Focus on Carvykti Milestones

CompanyDeals

Gilead Nears Completion of CymaBay Acquisition After Waiting Period Expires

CompanyDrug

J&J’s Tremfya Files for Ulcerative Colitis Indication with FDA, Building on Positive Late-Stage Data

CompanyDrug

Simcere Secures FDA Approval for Clinical Study of Trispecific Antibody SIM0500 in Multiple Myeloma

CompanyDrug

Everest Medicines’ Velsipity NDA Accepted in Macau, Poised for First Asian Approval

CompanyDrug

Lepu Biotechnology’s MRG004A ADC Gains Fast Track Designation for Pancreatic Cancer

CompanyDeals

Sichuan Biokin and Bristol-Myers Squibb Activate $800 Million ADC Licensing Deal

CompanyDeals

Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline

CompanyDrug

ClouDr Launches Dapagliflozin, Generic Version of AstraZeneca’s Forxiga, After NMPA Approval

CompanyDrug

BeiGene Launches Legal Action Against Sandoz and MSN Over Brukinsa Patent Infringement